Abstract Body

Background: Chronic HCV infection is the main cause of liver transplantation (LT). HCV recurrence, seen in ≈50% of HCV-infected LT patients during the first postoperative year, is the main cause of graft failure (despite long-term treatment with immunosuppressants eg cyclosporine [CSP] or tacrolimus [TAC]) and death in HCV-infected LT patients. Drug-drug interactions (DDIs) with CSP and TAC hinder the use of boceprevir and telaprevir in LT patients. Daclatasvir (DCV), a first-in-class HCV NS5A inhibitor with pan-genotypic activity in vitro anddemonstrated clinical efficacy as part of multiple (including all-oral) regimens, has a pharmacokinetic (PK) profile supportive of QD dosing and a low probability of DDIs as a perpetrator and manageable DDIs as a victim. It is anticipated that DCV will be co-administered with CSP and TAC in the clinical setting. Methodology: Healthy fasted subjects (age 18-49 years; BMI 18-32 kg/m2) received a single oral dose of CSP 400 mg on Days 1 and 9 and DCV 60 mg QD on Days 4-11 (Group 1), or received a single oral dose of TAC 5 mg on Days 1 and 13 and DCV 60 mg QD on Days 8-19 (Group 2). Blood samples for PK analysis were collected on Days 1 and 9 for CSP (72h), 1 and 13 for TAC (168h), and 8 and 9 (Group 1) or 12 and 13 (Group 2) for DCV (24h). Statistical analyses (geometric mean ratios [GMR] and 90% confidence intervals [CI]) on the PK parameters of CSP, TAC and DCV (max. plasma conc. [Cmax], AUC from time zero until the time of last quantifiable concentration [AUC0-τ],end of the dosing interval [AUC0-TAU] or extrapolated to infinity [AUC0-∞ ] and plasma conc. 24h post-dose [C24]) were performed. Results: Evaluable data from 14 subjects in each group were collected. DCV did not affect the PK parameters of either CSP or TAC, and TAC did not affect the PK parameters of DCV; all GMRs were close to 1 and the 90% CIs were contained within the accepted no-effect boundary (0.80-1.25). Coadministration of CSP resulted in modest increases in DCV AUC0-TAU (40%) and C24 (56%); Cmax was unaffected. Conclusions: No clinically-relevant DDIs were observed when DCV was co-administered with CSP or TAC; CSP caused a modest increase in DCV exposure. Dose adjustments for DCV, TAC, or CSP during co-administration of DCV with CSP or TAC are unlikely to be required.